Business Description
TONIX Pharmaceuticals is developing new therapies for challenging disorders of the central nervous system. The Company targets conditions characterized by significant unmet medical need, inadequate existing treatment options, and high dissatisfaction among both patients and physicians.
| Address: |
509 Madison Avenue, Suite 306, New York, NY 10022 |
| Telephone: |
(212) 980-9155 |
Website: |
www.tonixpharma.com |
| Fax: |
(212) 923-5700 |
Email: |
investor.relations@tonixpharma.com |
| IRS Disclosure: |
Form 8937  |
|
|
Details
| CEO: |
Seth Lederman |
| Issue Type: |
Common Stock |
| Auditors: |
EisnerAmper LLP |
Industry Classifications
| Sector: |
Healthcare |
| Industry: |
Drug Manufacture - Other |
| Sub-Industry: |
|
| NAICS: |
|
| SIC: |
|
|
